Millennium Management LLC Acquires 1,008,760 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Millennium Management LLC lifted its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 369.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,281,629 shares of the company's stock after buying an additional 1,008,760 shares during the quarter. Millennium Management LLC owned about 1.81% of Ventyx Biosciences worth $2,807,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Bank of America Corp DE increased its position in Ventyx Biosciences by 376.4% during the fourth quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock worth $9,359,000 after acquiring an additional 3,376,446 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Ventyx Biosciences during the fourth quarter worth approximately $276,000. Rhumbline Advisers increased its holdings in shares of Ventyx Biosciences by 44.4% during the fourth quarter. Rhumbline Advisers now owns 132,825 shares of the company's stock worth $291,000 after purchasing an additional 40,813 shares during the period. Renaissance Technologies LLC raised its position in shares of Ventyx Biosciences by 99.1% in the fourth quarter. Renaissance Technologies LLC now owns 624,500 shares of the company's stock valued at $1,368,000 after buying an additional 310,800 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Ventyx Biosciences by 14.2% in the fourth quarter. Barclays PLC now owns 91,669 shares of the company's stock valued at $200,000 after buying an additional 11,374 shares during the period. Institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Price Performance

NASDAQ:VTYX remained flat at $1.99 during trading hours on Wednesday. The company had a trading volume of 646,183 shares, compared to its average volume of 1,361,230. The firm has a fifty day moving average of $1.28 and a 200 day moving average of $1.72. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $5.66. The firm has a market capitalization of $141.61 million, a P/E ratio of -0.84 and a beta of 0.73.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. On average, equities research analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.